Reuters New YorkAugust 27, 2019UPDATED: August 27, 2019 12:22 IST Rafa Nadal will play his first round match against Australian John Millman. (Reuters Photo)HIGHLIGHTSNaomi Osaka will begin her US Open title defence on day two of the championshipsRafa Nadal will also play his first-round match against Australian John MillmanWimbledon champion Simona Halep will also get her campaign underway against local Nicole GibbsWorld number one Naomi Osaka begins her U.S. Open title defence on day two of the championships on Tuesday but there is likely to be as much interest in Cori Coco Gauff’s main draw debut at Flushing Meadows.In the men’s draw, three-times champion Rafa Nadal opens the evening session on the main Arthur Ashe Stadium show court with his first-round match against Australian John Millman.Gauff was born the year after Nadal played his first U.S. Open and the excitement around the young American has been growing since her stunning run to the last 16 at Wimbledon this year.The 15-year-old received a wild card into the singles draw and has also been awarded a spot on the Louis Armstrong Stadium show court for her opening match against Anastasia Potapova of Russia.Japan’s Osaka, still only 21, was the next big thing in tennis only a matter of months ago when she won the Australian Open to back up her maiden Grand Slam title in New York last year.Osaka will not only have to deal with the weight of expectation that comes with major titles and the top-ranking but also potentially the lingering impact of a knee injury that forced her to withdraw from the Cincinnati quarter-finals.Her match against Russia’s Anna Blinkova is the first on Arthur Ashe, where American Sloane Stephens, the 2017 champion, will close the day against Russian qualifier Anna Kalinskaya.Wimbledon champion Simona Halep will also get her campaign underway against local Nicole Gibbs, while the Grandstand Court hosts an intriguing match-up between Canadian young guns Denis Shapovalov and Felix Auger-Aliassime.advertisementAlso Read | US Open 2019: India’s Sumit Nagal gives Roger Federer a scare, goes down fighting in Round 1Also Read | Serena Williams cruises past Maria Sharapova to reach US Open second roundAlso See:For sports news, updates, live scores and cricket fixtures, log on to indiatoday.in/sports. Like us on Facebook or follow us on Twitter for Sports news, scores and updates.Get real-time alerts and all the news on your phone with the all-new India Today app. Download from Post your comment Do You Like This Story? Awesome! Now share the story Too bad. Tell us what you didn’t like in the comments Posted bySaurabh Kumar Tags :Follow US OpenFollow Naomi OsakaFollow Rafael Nadal Naomi Osaka, Rafael Nadal open campaigns on day two of US OpenNaomi Osaka’s match against Russia’s Anna Blinkova is the first on Arthur Ashe, where American Sloane Stephens, the 2017 champion, will close the day against Russian qualifier Anna Kalinskaya.advertisement Next
Want the best of The Telegraph direct to your email and WhatsApp? Sign up to our free twice-daily Front Page newsletter and new audio briefings. MS is an incurable, neurological condition in which the immune system mistakes myelin – the protective coating around nerves for a foreign body and attacks it.The damage stops messages from being passed along the nerves, leading to symptoms including tiredness and blurred vision.Ocrelizumab works by killing the cell which attacks the myelin sheath.Dr Aisling McMahon, the head of clinical trials at the MS Society, said: “This is really big news for people with the primary progressive form of multiple sclerosis.”It’s the first time a treatment has shown the potential to reduce disability progression for this type of MS, which offers a lot of hope for the future.” One study of 732 patients with progressive MS, published in the New England Journal of Medicine, found 33 per cent of people deteriorated when they were taking ocrelizumab, compared with 39 per cent without.In another study of 1,656 patients with relapsing remitting MS, the relapse rate for patients taking ocrelizumab was half what it was with a different drug.Prof Gavin Giovannoni, the chair of neurology from Barts and The London School of Medicine and Dentistry, who was involved in the trials, told the BBC the results have the potential to change treatments for patients suffering from both kinds of MS.He added: “It’s very significant because this is the first time a phase three trial has been positive in primary progressive MS.” Show more It’s very significant because this is the first time a phase three trial has been positive in primary progressive MSProf Gavin Giovannoni The first drug to slow primary progressive multiple sclerosis has been hailed as “big news” by doctors and charities.Ocrelizumab is now being reviewed for use in Europe and the United States after trials showed it may slow damage to the brain.Researchers have also suggested that the drug can prevent deterioration in patients with relapsing remitting MS, which is when symptoms come in waves.